Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy.

Brock C, Hansen CS, Karmisholt J, Møller HJ, Juhl A, Farmer AD, Drewes AM, Riahi S, Lervang HH, Jakobsen PE, Brock B

British journal of clinical pharmacology30 Aug 2019Cited by 82 (Europe PMC)

PMID31338868PMCIDPMC6848951DOI10.1111/bcp.14063PepBankPUB-31338868

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes and polyneuropathy, liraglutide did not change neuronal function at the central level.
In plain wordsIn adults with type 1 diabetes and nerve damage, liraglutide did not change how well the brain nerves worked.
Peptide
Liraglutide
Outcome
No significant changeCentral neuronal function (evoked potentials)
Study
n = 39
Comparator
Placebo
Analysis
Primary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
1.2-1.8 mg/d · 26 weeks (after 6 weeks of titration)As given in this study (human).
Source sentences
Summary
However neuronal function was unaltered at the central, autonomic or peripheral level.
4 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was change in latency of early brain evoked potentials.
Summary · context
The study was a randomized, double-blinded, placebo-controlled trial of adults with type 1 diabetes and confirmed symmetrical polyneuropathy.
Summary · context
Titration was 6 weeks to 1.2-1.8 mg/d, continuing for 26 weeks.
Summary · context
Thirty-nine patients completed the study, of whom 19 received liraglutide.
Report a problemFND-3133886803
02HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes and polyneuropathy, liraglutide reduced interleukin-6 by 22.6% compared with placebo.
In plain wordsIn adults with type 1 diabetes and nerve damage, liraglutide lowered interleukin-6, a marker of inflammation, more than placebo.
Peptide
Liraglutide
Outcome
DecreaseInterleukin-6 change
Study
n = 39
Comparator
Placebo
Analysis
Secondary
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
1.2-1.8 mg/d · 26 weeks (after 6 weeks of titration)As given in this study (human).
Measurements
IL-6 difference vs placebo
−22.6%
liraglutide
Source sentences
Summary
In comparison to placebo, liraglutide reduced interleukin-6 (-22.6%; 95% confidence interval [CI]: -38.1, -3.2; P = .025
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a randomized, double-blinded, placebo-controlled trial of adults with type 1 diabetes and confirmed symmetrical polyneuropathy.
Summary · context
Titration was 6 weeks to 1.2-1.8 mg/d, continuing for 26 weeks.
Summary · context
Thirty-nine patients completed the study, of whom 19 received liraglutide.
Report a problemFND-3133886801
03HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes and polyneuropathy, other proinflammatory cytokines showed numerical reductions with liraglutide; the abstract gives no significance for them.
In plain wordsIn adults with type 1 diabetes and nerve damage, other inflammation markers were numerically lower with liraglutide, with no significance reported.
Peptide
Liraglutide
Outcome
DecreaseOther proinflammatory cytokines
Study
n = 39
Comparator
Placebo
Analysis
Secondary
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
1.2-1.8 mg/d · 26 weeks (after 6 weeks of titration)As given in this study (human).
Source sentences
Summary
with concomitant numerical reductions in other proinflammatory cytokines.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a randomized, double-blinded, placebo-controlled trial of adults with type 1 diabetes and confirmed symmetrical polyneuropathy.
Summary · context
Titration was 6 weeks to 1.2-1.8 mg/d, continuing for 26 weeks.
Summary · context
Thirty-nine patients completed the study, of whom 19 received liraglutide.
Report a problemFND-3133886802
04HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes and polyneuropathy, liraglutide did not change autonomic neuronal function.
In plain wordsIn adults with type 1 diabetes and nerve damage, liraglutide did not change how well the automatic body nerves worked.
Peptide
Liraglutide
Outcome
No significant changeAutonomic neuronal function
Study
n = 39
Comparator
Placebo
Analysis
Secondary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
1.2-1.8 mg/d · 26 weeks (after 6 weeks of titration)As given in this study (human).
Source sentences
Summary
However neuronal function was unaltered at the central, autonomic or peripheral level.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a randomized, double-blinded, placebo-controlled trial of adults with type 1 diabetes and confirmed symmetrical polyneuropathy.
Summary · context
Titration was 6 weeks to 1.2-1.8 mg/d, continuing for 26 weeks.
Summary · context
Thirty-nine patients completed the study, of whom 19 received liraglutide.
Report a problemFND-3133886804
05HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes and polyneuropathy, liraglutide did not change peripheral neuronal function.
In plain wordsIn adults with type 1 diabetes and nerve damage, liraglutide did not change how well the nerves in the limbs worked.
Peptide
Liraglutide
Outcome
No significant changePeripheral neuronal function
Study
n = 39
Comparator
Placebo
Analysis
Secondary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
1.2-1.8 mg/d · 26 weeks (after 6 weeks of titration)As given in this study (human).
Source sentences
Summary
However neuronal function was unaltered at the central, autonomic or peripheral level.
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a randomized, double-blinded, placebo-controlled trial of adults with type 1 diabetes and confirmed symmetrical polyneuropathy.
Summary · context
Titration was 6 weeks to 1.2-1.8 mg/d, continuing for 26 weeks.
Summary · context
Thirty-nine patients completed the study, of whom 19 received liraglutide.
Report a problemFND-3133886805
06HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes and polyneuropathy, liraglutide treatment was associated with a weight loss of 3.38 kg.
In plain wordsIn adults with type 1 diabetes and nerve damage, liraglutide treatment was linked to a weight loss of 3.38 kg.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 39
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2-1.8 mg/d · 26 weeks (after 6 weeks of titration)As given in this study (human).
Measurements
Weight change
−3.38 kg
liraglutide
Source sentences
Summary
Treatment was associated with -3.38 kg (95% CI: -5.29, -1.48; P < .001] weight loss
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a randomized, double-blinded, placebo-controlled trial of adults with type 1 diabetes and confirmed symmetrical polyneuropathy.
Summary · context
Titration was 6 weeks to 1.2-1.8 mg/d, continuing for 26 weeks.
Summary · context
Thirty-nine patients completed the study, of whom 19 received liraglutide.
Report a problemFND-3133886806
07HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes and polyneuropathy, liraglutide treatment was associated with a 40.2% decrease in urine albumin/creatinine ratio.
In plain wordsIn adults with type 1 diabetes and nerve damage, liraglutide treatment was linked to a lower urine albumin/creatinine ratio, a kidney marker.
Peptide
Liraglutide
Outcome
DecreaseUrine albumin/creatinine ratio change
Study
n = 39
Outcome group
Kidney function · Kidney and urinary
Studied dose
1.2-1.8 mg/d · 26 weeks (after 6 weeks of titration)As given in this study (human).
Measurements
UACR change
−40.2%
liraglutide
Source sentences
Summary
a decrease in urine albumin/creatinine ratio (-40.2%; 95% CI: -60.6, -9.5; P = .02).
3 context sentences(design, population, supporting numbers)
Summary · context
The study was a randomized, double-blinded, placebo-controlled trial of adults with type 1 diabetes and confirmed symmetrical polyneuropathy.
Summary · context
Titration was 6 weeks to 1.2-1.8 mg/d, continuing for 26 weeks.
Summary · context
Thirty-nine patients completed the study, of whom 19 received liraglutide.
Report a problemFND-3133886807

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT02138045

Treatment of Diabetic Neuropathy With Liraglutide

Aalborg University Hospitaln = 39May 2014 to Feb 2017

Diabetes Mellitus, Type 1 · Type 1 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 10 Aug 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy.

Summary

Results from this study7

Registered trials1

Treatment of Diabetic Neuropathy With Liraglutide

Version history

Subjects

Publication types

MeSH terms

Keywords